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Background: Epidemiologic studies combining exposure and outcome data with the collection 
of biosamples are needed to study gene–environment interactions that might contribute to the 
etiology of complex diseases such as pediatric Crohn’s disease (CD). Nationwide registries, 
including those in Denmark and other Scandinavian countries, provide efficient and reliable 
sources of data for epidemiological studies evaluating the environmental determinants of disease. 
We performed a pilot study to test the feasibility of collecting salivary DNA to augment registry 
data in established cases of pediatric CD and randomly selected, population-based controls.
Subjects and methods: Cases of CD born after 1995 and residing in the central region 
of Denmark were identified through the Danish National Patient Registry and confirmed by 
using standard diagnostic criteria. Age- and gender-matched controls were selected at random 
through the civil registration system. Cases and controls were contacted by mail and telephone 
and invited to submit a saliva sample. DNA was extracted and genotyped for six CD-associated 
single-nucleotide polymorphisms (SNPs).
Results: A total of 53 cases of pediatric CD were invited, and 40 contributed a saliva sample 
(75% response rate). A total of 126 controls were invited, and 54 contributed a saliva sample 
(44% response rate). As expected, demographic characteristics did not differ between cases and 
controls. DNA was successfully isolated from 93 of 94 samples. Genotyping was performed 
with only 2% undetermined genotypes. For five of six SNPs known to be associated with CD, 
risk allele frequencies were higher in cases than controls.
Conclusion: This pilot study strongly supports the feasibility of augmenting traditional epide-
miological data from Danish population-based registries with the de novo collection of genetic 
information from population-based cases and controls. This will facilitate rigorous studies of 
gene–environment interactions in complex chronic conditions such as CD.
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Background
Crohn’s disease (CD), believed to affect nearly 10,000 Danes1 and 600,000 Americans,2 
is a chronic, idiopathic, inflammatory bowel disease (IBD) that results in substantial 
morbidity, including frequent hospitalization and surgery,3,4 missed work5 and school,6 
and reductions in quality of life.7,8 Nearly 10% of cases are diagnosed during child-
hood and adolescence, and early-onset IBD is considered to be a particularly severe 
phenotype. The pathogenesis is believed to involve dysregulation of the gastrointestinal 
immune response to environmental factors, such as commensal enteric bacteria.9 The 
genetic predisposition for this condition, long suggested by the approximately 50% 
concordance in identical twins,10,11 has received further support over the past few years 
Correspondence: Michael D Kappelman 
Department of Pediatrics, Division of 
Pediatric Gastroenterology, University of 
North Carolina at Chapel Hill, 130 Mason 
Farm Road, Campus Box 7229, Chapel 
Hill, NC 27599, USA 
Tel +1 919 966 1343 
Fax +1 919 966 8641 
Email michael_kappelman@med.unc.edu
Journal name: Clinical Epidemiology
Article Designation: ORIGINAL RESEARCH
Year: 2018
Volume: 10
Running head verso: Kappelman et al
Running head recto: Salivary DNA collection in pediatric Crohn’s and population controls
DOI: http://dx.doi.org/10.2147/CLEP.S143322
Powered by TCPDF (www.tcpdf.org)
                               1 / 1





as recent genome-wide association studies have revealed at 
least 163 susceptibility loci for IBD, emphasizing the range 
and complexity of pathways that may be involved.12
Despite these strong genetic influences, evidence also 
suggests a critical role of environmental factors. First, about 
50% of monozygotic twins are discordant for CD, despite 
identical genetic makeup. Second, incidence rates have risen 
dramatically between 1960 and 1990 in a number of North 
American and European populations, more than would be 
expected based on Mendelian inheritance alone.13 In addition, 
the incidence of IBD has increased exponentially in formerly 
low-incidence areas including Asia and Latin America, possi-
bly reflecting the “westernization” of these regions including 
changes in diet, lifestyle, medication use, and perhaps other 
environmental exposures.13 Nevertheless, studies examining 
the role of specific environmental risk factors (with the excep-
tion of tobacco smoke) have been disappointing, yielding 
either contradictory or inconclusive results, perhaps due to 
design limitations resulting in recall and/or referral biases 
and the lack of study of gene–environment interactions. In 
complex conditions such as CD, gene–environment interac-
tions have been hypothesized, as the effects of environmental 
exposures may be dependent on genetic predisposition.14
The ideal study design to evaluate the etiology of a com-
plex, chronic illness that likely involves gene– environment 
interactions, such as CD, would be a population-based 
study that combines the measurement of environmental 
exposures with the collection of genetic factors. Denmark, 
with a population of some 5 million people, is well suited 
for epidemiological studies designed to evaluate both the 
genetic and environmental determinants of complex ill-
nesses such as childhood CD. Since the 1930s, the Danish 
government has compiled hundreds of databases to monitor 
the demographics, health, occupational status, and other 
socioeconomic factors affecting its population. Importantly, 
each citizen has a unique personal identification number that 
can be used to tie these individual databases together and 
track individuals across their lifespan.15,16 Furthermore, the 
personal identification number can also be used to locate 
individuals and solicit participation in epidemiological 
studies requiring additional primary data collection, and/or 
collection of biological specimens. This infrastructure makes 
it theoretically possible to conduct methodologically rigorous 
population-based epidemiological studies that combine the 
use of existing, prospectively collected administrative data 
with collection and banking of biological samples.
While the collection and banking of DNA from blood 
samples of clinical populations (cases) has been common 
practice for decades, the ability to collect DNA from ran-
domly selected, population-based controls presents a logisti-
cal challenge. However, in recent years, the ability to extract 
DNA from saliva samples has made it theoretically possible 
for both cases and controls to collect saliva in the comfort of 
their own home and ship the samples by mail for subsequent 
extraction and analyzing of DNA. This would eliminate the 
need for venipuncture and/or study visits, important bar-
riers to recruitment in population-based studies. Whether 
cases and population-based controls would be willing and 
able to provide a salivary DNA sample, especially in child-
hood, remains unknown. We therefore performed a pilot and 
feasibility study to test methods for the collection, storage, 
extraction, and genotyping of salivary DNA in confirmed 
cases of pediatric CD along with age- and gender-matched 
population controls. If feasible, this would lay the founda-
tion for large, population-based studies of gene–environment 




We performed a pilot study to collect and analyze salivary 
DNA from population-based cases of pediatric CD and age- 
and gender-matched controls. We identified cases born after 
1995 and residing in the central region of Denmark through 
the Danish National Patient Registry using Crohn’s specific 
ICD-10 codes K50. The Danish National Patient Registry 
has kept records of all nonpsychiatric discharge diagnoses 
since 1977 and outpatient visits since 1995.17 All CD cases 
identified through this registry were reviewed by a pediatric 
gastroenterologist (AL) using standard diagnostic criteria.18 
Patients without a confirmed diagnosis of CD were excluded.
An overview of study recruitment processes is shown in 
Figure 1. The parents of confirmed cases were mailed a letter 
describing the study and offered more information about the 
study participation. If a response form was not returned to the 
study team within 3 weeks, a reminder letter was sent to the 
parents. Parents who returned a response form stating they 
would like to know more about the study were contacted by 
telephone by a pediatric gastroenterologist (AL) to discuss 
the purpose and procedures of the study and answer any 
questions. The parents of cases were also provided additional 
study-related information during study, office appointments. 
Parents were then mailed a written consent form along with a 
salivary DNA collection kit (Oragene; DNA Genotek, Ottawa, 
ON, Canada), self-collection instructions, and a prepaid 
return envelope. We utilized Oragene OG-500 kits for saliva 
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Salivary DNA collection in pediatric Crohn’s and population controls
Figure 1 Flow diagram of recruitment procedures for the collection of saliva from DNA extraction from population-based cases of pediatric CD and randomly selected 
controls in the central region of Denmark.





Letter, informed consent form, saliva collection kit, prepaid envelope
Sample returned with valid consent
form = enrolled
Thank you for participating Thank you for participating
Letter and gift card Letter, new consent form, prepaid envelope, gift card
Valid consent form returned = enrolled Invalid consent form = not enrolled
Sample returned with invalid consent form
No Response
No Response
Reminder letter after 3 weeks
Yes, we would like to know more
Yes, we would like to know more
Yes, we would like to
participate





Letter, folder with detailed study information, response form, prepaid envelope
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collection, as this method has been previously demonstrated 
to provide high-quality genomic DNA.19 Upon collection, the 
saliva sample is stable at room temperature for up to 1 year, 
eliminating the need for immediate laboratory extraction. 
Participants were instructed not to eat, drink, smoke, or chew 
gum 30 minutes before sample collection. Upon collection, 
samples were mailed at ambient temperature without ice to 
the Department of Clinical Epidemiology at Aarhus University 
and subsequently batch shipped to the University of North 
Carolina at Chapel Hill for DNA extraction and analysis. 
As an incentive for participation, participants were mailed a 
gift card worth 100 Danish Krone (DKK) (approximately 15 
USD) once they had returned a saliva sample.
For each case, we selected age-, gender-, and region-
matched controls at random through the civil registration 
system. To ensure that controls were truly population based, 
there were no exclusion criteria for controls. As with cases, 
the parents of selected controls were mailed a letter describ-
ing the study and offered additional information about the 
study participation. A reminder letter was sent as necessary. 
Parents who returned a response form stating they would like 
to know more about the study were contacted by telephone 
by a trained member of the study team to discuss the study 
in more detail and were then mailed a written consent form 
along with a salivary DNA collection kit. Controls received 
the same participation incentive as cases.
DNA extraction and genotyping
All salivary DNA collection kits returned with a valid, signed 
informed consent form were batch shipped to the University 
of North Carolina at Chapel Hill for DNA extraction, stor-
age, and analysis.
DNA was extracted from saliva samples using the 
Chemagic Magnetic Separation Module I (MSMI) robotic 
system (PerkinElmer Inc., Waltham, MA, USA), using 
the Chemagic DNA Saliva Kit and the MSMI 24 rod 
head. The MSMI system isolates DNA after cell lysis via 
highly specific binding of the DNA to proprietary magnetic 
particles based on polyvinyl alcohol (M-PVA) magnetic 
beads. Once bound, the DNA was washed several times 
and then released from the magnetic beads. Optical density 
readings were taken on a Nanodrop to assess the 260/280 
and 260/230 ratio quality metrics. DNA quantitation was 
assessed via Picogreen using the Quant-iT PicoGreen 
dsDNA Assay Kit cat# P7589 (Thermo Fisher Scientific, 
Waltham, MA, USA).
DNA was genotyped for six CD-associated single-
nucleotide polymorphisms (SNPs) using TaqMan SNP 
Genotyping Assays from Thermo Fisher Scientific. SNPs 
of interest were selected by first performing a literature 
search for loci of interest for CD, ulcerative colitis (UC), or 
IBD,12,20–25 and findings were narrowed to loci that demon-
strated relatively large proportion of variance or relatively 
high odds ratios for IBD versus control.12 Selected SNPs 
included those for NOD2 (rs2066844, rs2066845, and 
rs2066847), ATG16L1 (rs12994997), IL23R (rs11209026), 
and MUC 19 (rs11564258).12,26,27 We used pre-designed 
assays for all but one SNP (rs2066847), for which a custom 
primer was designed using previously established sequences 
(forward primer: GTCCAATAACTGCATCACCTACCT; 
reverse primer: CAGACTTCCAGGATGGTGTCATTC, 
probe 1 – VIC-MGB; dye: CAGGCCCCTTGAAAG, probe 
2 – FAM-MGB; dye: CAGGCCCTTGAAAG).28 Polymerase 
chain reaction (PCR) volume was 5 mL.
Sample size
Our targeted sample size was approximately 50 cases and 50 
controls to provide a rough estimate of the feasibility of case 
and control recruitment and to allow accurate genotyping for 
SNPs with low minor allele frequencies.
Statistical analysis
We used descriptive statistics and Student’s t-tests or Fisher’s 
exact test as applicable for comparisons between groups. As 
this was a pilot study, we specifically did not perform sta-
tistical comparisons for genetic analyses. All statistics were 
computed using SAS version 9.3. The study protocol was 
approved by the Danish Data Protection Agency (J.no. 2010-
41-4888), the Scientific Ethical Board of Central Denmark 
Region (J. no. 1-10-72-372-12), and the University of North 
Carolina at Chapel Hill.
Results
Study population
A total of 53 cases of pediatric CD were invited, and 40 
contributed a saliva sample along with valid consent (75% 
response rate). The mean age of cases who contributed a 
sample was 15 years (SD=2.4); 35% were female. The mean 
age of nonresponder cases was 14.9 years; 54% were female. 
A total of 126 controls were invited, and 54 contributed a 
saliva sample along with a valid consent (44% response 
rate). The mean age of controls who contributed a sample 
was 15.2 years (SD=2.4); 37% were female. The mean age 
of nonresponder cases was 15.8 years; 23% were female. 
As expected, demographics did not differ between cases and 
controls (Table 1).
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Salivary DNA collection in pediatric Crohn’s and population controls
DNA extraction and yield
Of 94 samples received, one leaked (case sample) in trans-
port. DNA was successfully isolated from the 93 remaining 
samples. The total DNA yield ranged from 3.11 to 100.34 mg 
(median 58.20 mg), and 89% (83/93) of the samples yielded 
>20 mg.
Genotyping
All samples were genotyped for six SNPs associated with 
IBD, and risk allele frequencies (RAFs) were calculated. Of 
564 possible genotypes, only 11 (2.0%) were undetermined. 
The RAFs for cases and controls are provided in Table 2. 
Genotypes are provided in Table S1. For five of six SNPs 
analyzed (83%), the RAFs in cases and controls were all in 
the expected direction based on prior literature. The only 
exception was for rs206845 whose RAF was 0.01 in cases 
and 0.02 in controls.
Discussion
Epidemiologic studies combining exposure and outcome data 
with the collection of biosamples are needed to study gene–
environment interactions that might contribute to the etiology 
of complex diseases such as pediatric CD. Nationwide reg-
istries, including those in Denmark and other Scandinavian 
countries, provide efficient and reliable sources of data for 
epidemiological studies evaluating the environmental deter-
minants of disease. In this pilot study, we have demonstrated 
the capacity to augment registry data through the collection 
of salivary DNA by mail in both cases, and most importantly, 
valid, randomly selected, population-based controls. This 
includes home saliva collection, shipping, storage, DNA 
extraction, and genotyping.
Specifically, we found a very high response rate of 75% 
among cases of pediatric CD, and a reasonably high response 
rate of 44% for randomly selected, age- and gender-matched 
controls. DNA was successfully extracted from 93 of 94 
collected samples, with a median yield of 58.20 mg of DNA 
per sample. Genotyping was successfully performed on all 
samples. Overall, only 2% of all genotypes were undeter-
mined. In addition, even in this small pilot study, we were 
able to replicate previously established genetic associations 
for five of the six selected genotypes, further demonstrating 
the utility of augmenting population-based registry studies 
with genetic analyses.
The response rates observed in this study warrant par-
ticular consideration. First, the 75% response rate among 
CD patients was outstanding. To our knowledge, this is 
the only study of the response rate for a population-based 
genetic study of a pediatric illness. However, our response 
rate was similar to that observed in other highly engaged 
populations, including participants in a Danish nursing 
cohort study29 and a US-based cohort of adult patients with 
IBD.30 We believe that the high response rate among cases 
likely reflects a patient population that is highly motivated 
to contribute IBD research  for both personal and altruistic 
reasons.31 In addition, we utilized office visits, in addition 
to mail/telephone to contact potential participants and pro-
vide them with information about the study. Future genetic 
epidemiology studies may also benefit by augmenting mail/
telephone recruitment with office-based contact.
The response rate of 44% among randomly selected 
controls is also notable. While the expected response rate 
of randomly selected, population-based, pediatric controls 
to a genetic study is unknown, our observed response rate 
seems quite robust given that the response rates to survey/
interview studies in adults are in the range of 42%–64%,32–34 
and one might have expected a lower response rate for a 
genetic study in children. Furthermore, we believe the pos-
sibility of nonresponse bias is likely to be low in studies of 
gene–environment interactions, as this would require a gene 
associated with both nonresponse and disease susceptibility.
The strengths of this study include the use of a population-
based registry to identify cases and randomly select potential 
controls and the confirmation of all cases by an experienced 
Table 1 Demographics of pediatric CD cases and controls
Case (n=40) Control (n=54) p
Mean age, years (SD) 15.2 (2.4) 15.3 (2.4) 0.78
Median age, years 
(IQ range)
15.7 (13.2–17.3) 16.3 (13.1–17.5) 0.68
Female, % 14 (35.0) 20 (37.0) 1.00
Birth year, n (%)
1995–1997 21 (52.5) 28 (51.9) 0.79
1998–2000 12 (30.0) 14 (25.9)
2001–2003 7 (17.5) 12 (22.2)
Abbreviation: CD, Crohn’s disease.
Table 2 RAFs for selected SNPs in population-based pediatric 
CD cases and controls in the central region of Denmark
SNP Gene Case Control
rs12994997 ATG16L1 0.69 0.43
rs2066844 NOD2 0.03 0.01
rs2066845 NOD2 0.01 0.02
rs2066847 NOD2 0.04 0.02
rs11564258 MUC19 0.03 0.02
rs11209026A IL23R 0.01 0.06
Notes: AThe rs11209026 SNP codes for a protective allele. Therefore, a higher 
allele frequency is expected in the control group.
Abbreviations: CD, Crohn’s disease; RAFs, risk allele frequencies; SNP, single-
nucleotide polymorphism.
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pediatric gastroenterologist. An additional strength was the use 
of a centralized approach to contact potential controls using only 
mail and telephone, as this approach can be readily scaled to 
facilitate large, population-based studies. As with all pilot proj-
ects, the main limitation of this work was the limited number of 
participants which precluded our ability for hypothesis testing 
of genetic associations between cases and controls. In addition, 
while our recruitment target was 50 cases, we fell short of this as 
only 40 cases contributed a sample with valid consent. Another 
possible limitation is that some patients with CD (diagnosed or 
undiagnosed) did not have the relevant ICD-10 diagnosis code 
recorded in the Danish National Registry of Patients (DNRP) 
and may have been misclassified as controls. However, given 
the low prevalence of pediatric CD, the potential for misclas-
sification of cases as controls is extremely low.
Conclusion
This pilot study strongly supports the feasibility of studies 
that combine the use of traditional epidemiological expo-
sure and outcome data from population-based registries 
with the de novo collection of genetic information from 
true, population-based cases and controls. This model will 
facilitate rigorous studies of gene–environment interactions 
that are particularly important for conditions such as pedi-
atric CD and other complex chronic conditions for which 
there are no medical or surgical cures, making prevention 
of paramount importance. These future studies will fill a 
critical unmet need, as prior epidemiological studies of IBD 
have not included measures of genetic risk and the large-scale 
genetic studies have not included simultaneous measures of 
environmental and/or pharmacological exposures.
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Table S1 Genotypes for selected SNPs in population-based pediatric CD cases and controls in the central region of Denmark
Genotype rs12994997 rs2066844 rs2066845 rs2066847 rs11564258 rs11209026*
Case Control Case Control Case Control Case Control Case Control Case Control
Homozygous risk allele 20 10 0 0 0 0 0 0 0 0 0 0
Homozygous reference allele 5 17 36 50 37 50 36 52 37 50 37 46
Heterozygous 14 25 2 1 1 2 3 2 2 2 1 6
Undetermined 0 2 1 3 1 2 0 0 0 2 1 2
Note: *Homozygous “risk” allele confers protection against disease for this SNP.
Abbreviations: CD, Crohn’s disease; SNP, single-nucleotide polymorphism.
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